Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where analysts may be overlooking some important risks.

Consensus Price Target: $38 (39.6% implied return)

Spanning a broad range of styles, brands, and prices, Genesco (NYSE:GCO) sells footwear, apparel, and accessories through multiple brands and banners.

Why Do We Avoid GCO?

Disappointing same-store sales over the past two years show customers aren’t responding well to its product selection and in-store experience

Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

8× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly

Genesco’s stock price of $27.23 implies a valuation ratio of 16x forward P/E. If you’re considering GCO for your portfolio, see our FREE research report to learn more.

Consensus Price Target: $4 (125% implied return)

Formed from a partnership between two distinct companies, CVG (NASDAQ:CVGI) offers various components used in vehicles and systems used in warehouses.

Why Are We Out on CVGI?

Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last five years

Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

High net-debt-to-EBITDA ratio of 5× could force the company to raise capital at unfavorable terms if market conditions deteriorate

Commercial Vehicle Group is trading at $1.78 per share, or 9.6x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than CVGI.

Consensus Price Target: $364.63 (24.9% implied return)

With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care.

Why Does UNH Stand Out?

Decent 11.7% annual revenue growth over the last five years beat most of its peers, showing customers find value in its products and services

Enormous revenue base of $447.6 billion gives it leverage over plan holders and advantageous reimbursement terms with healthcare providers

ROIC punches in at 19.6%, illustrating management’s expertise in identifying profitable investments

At $291.94 per share, UnitedHealth trades at 16x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.